Chat with Filing

Ask questions about this document
Please log in or register to use the chat feature. Please register first.
RNS - US Reimbursement milestone for Speedboat procedure

Company: CREO MEDICAL GROUP PLC Date: 2025-05-28 Language: English Register to download
Loading document preview...
Document Preview Not Available

The file type (.html) cannot be displayed directly here.
Open Original File
Error loading document preview. Please try the 'Open Original File' link.
You're One Click Away From The Full Filing

Instantly access this document—and 2.8M more—for free. Select your preferred method:
Continue with Google Continue with Microsoft Continue with Facebook Continue with Amazon
 National Storage Mechanism | Additional information  ![](https://tracker.live.rns-distribution.com/track.live-rns/5670582_d9353a075fe0b610698e373da828b7e4.png)

RNS Number : 3102K

Creo Medical Group PLC

28 May 2025

Creo Medical Group plc

("Creo", the "Company" or the "Group")

US Reimbursement milestone for Speedboat procedure

Further driving the roll-out of Creo's products

Creo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of minimally invasive surgical endoscopy for pre-cancer and cancer patients, announces that the American Medical Association ("AMA") Current Procedural Terminology (CPT®) Editorial Panel has issued its Summary of Panel Actions confirming the establishment of two new Category I CPT reimbursement codes for Endoscopic Submucosal Dissection ("ESD") procedures - one for the upper gastrointestinal ("GI") tract and a second for the lower GI tract. 

The establishment of dedicated CPT codes provides a clear reimbursement framework for U.S. healthcare providers to offer this advanced, organ-preserving procedure to a broader patient population.  ESD is a precision technique used to remove early-stage cancerous and pre-cancerous lesions from the GI tract via an endoscope, eliminating the need for open surgery or segmental organ removal. It allows for more accurate pathology and has been associated with lower recurrence rates, faster recovery, and fewer complications.

Creo Medical collaborated with a consortium of medical societies, key opinion leaders and industry partners to gather peer-reviewed clinical data illustrating improved clinical outcomes, and procedural data highlighting the growing adoption of GI ESD procedures in the clinical community. This collaborative effort demonstrated the safety, efficacy, and long-term benefits of ESD, reinforcing its value in delivering better patient outcomes and supporting its recognition through formal CPT coding.

It is estimated that around 5% of the U.S. population over the age of 50 could potentially benefit from an ESD procedure. The data suggest that indications potentially suitable for ESD treatment are diagnosed in between 5% and 10% of the annual c.16 million U.S. colonoscopies performed. The establishment of re-imbursement for lower GI ESD will open up access to this procedure to a much larger proportion of these US patients with the clinical benefits demonstrated.

The establishment of these reimbursement codes will also help drive continued medical innovation by enabling and encouraging the use of next-generation products such as Creo's Speedboat® UltraSlim, and Speedboat® Notch designed specifically for ESD. All Creo's products are designed to empower clinicians with greater precision, safety, and procedural efficiency for complex endoscopic interventions.

For more information about ESD and Creo Medical's full portfolio of unique advanced energy products, visit:  [www.creomedical.com/esd](http://www.creomedical.com/esd)

Commenting, Craig Gulliford, Chief Executive Officer, said :

"This is a transformative moment for patients, clinicians, and the broader GI community. The AMA's decision to establish dedicated CPT codes for ESD will help remove barriers to access, enabling broader adoption of this advanced, minimally invasive procedure in the U.S. We are proud to have worked alongside leading societies, key opinion leaders, and industry partners to build the clinical evidence base needed to support this milestone. With clearer reimbursement pathways now in place, more patients will benefit from safer, and more effective treatment options utilising Creo's range of products."

  

  

For further information please contact:  

|     |     |     |
| --- | --- | --- |
| Creo Medical Group plc |     | [www.creomedical.com](https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4) |
| Richard Craven, Company Secretary |     | Via Walbrook PR |
|     |     |     |
| Deutsche Numis (Nominated Adviser, sole Broker and Financial Adviser)<br><br>Freddie Barnfield / Duncan Monteith / Euan Brown / Sher Shah |     | +44 (0)20 7260 1000 |
|     |     |     |
| Walbrook PR Ltd | Tel: +44 (0)20 7933 8780 or  [creo@walbrookpr.com](mailto:creo@walbrookpr.com) |     |
| Paul McManus / Alice Woodings | Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |     |
|     |     |     |

![](https://dw6uz0omxro53.cloudfront.net/3401425/5891247d-48d9-4320-a906-9b598819b486.png)

About Creo Medical

Creo is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation, and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less invasive and more cost-efficient option for procedures.

For more information, please refer to the website [www.creomedical.com](https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com/).  

  

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](https://www.lseg.com/privacy-and-cookie-policy).

END

MSCPPUCWAUPAPUM